USP and Public Policy
Left
Refine Your Search
USP supports comprehensive policies and programs to address AMR, including building capabilities among global stakeholders to reduce the proliferation of poor-quality medicines and advocating and…
Learn More
USP supports a comprehensive public policy framework to combat substandard and falsified medicines, including advancing stewardship of quality pharmaceutical products and practices, and building the…
Learn More
USP Comment Letter to Senators Sanders and Cassidy and Representatives McMorris-Rodgers and Pallone ( ranking members of the Senate HELP Committee and House Energy and Commerce Committee) regarding…
Learn More
USP Comment Letter to FDA on Advanced Manufacturing Technologies Designation Program; Draft Guidance for Industry. Submitted on March 12, 2024.
Learn More
USP Global Public Policy Position on advanced manufacturing technologies (AMTs) for medical products. Published in 2024.
Learn More
Identifying and addressing vulnerabilities in the upstream pharmaceutical supply chain are essential to mitigating and preventing drug shortages and to ensuring patients have access to the critical…
Learn More
USP Global Public Policy Position: Fostering the Use of Novel Excipients in Drug Products; Published 2024.
Learn More
USP Global Public Policy Position published 2024
Learn More
USP Comment Letter to FDA on Strategy Document on Innovative Manufacturing Technologies (2024). Submitted on November 11, 2024.
Learn More
USP Comment Letter: Submitted to The National Institutes of Health (NIH) Office of Dietary Supplements (ODS) draft CY 2025- 2029 Strategic Plan (2024). Submitted on August 20, 2024.
Learn More